♥

Procter & Gamble Health Limited

ISIN : INE199A01012
NSE : PGHL
BSE : 533081
Face Value : 10
Industry : Pharmaceuticals & Drugs

EPS : 121.07
EPS (TTM) : 121.01
Price to Earning (P/E) : 42.51
Book Value : 447.62
Price to Bookvalue (P/B) : 11.50
Dividend Yield : 2 %
Return on Equity (ROE) : 33.94 %
Return on Capital Employed (ROCE) : 46.07 %

Procter & share price (28-Mar-2025)
National Stock Exchange NSE
Open / Close	5002.6 - 5146.5 2.9 %
Low / High	5002.6 - 5203.05 4 %
Trade Volume	11,171
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %

YOU MAY ALSO LIKE

High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Share Market basics for beginners
Share Market jargons in simple terms
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Stock market course tutorial
Stock Market Investment Course explained in simple words.
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR PROCTER & GAMBLE HEALTH LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	2678.2	2958.9	2975.5	3099.7	3209.2	3011.8	3049.3	3099.7	2524.8	2838.8
Total Income	2701.7	2989.9	3009.7	3145.1	3258.9	3066.4	3109.8	3151.5	2547.5	2860.1
Total Expenditure	1990.5	2368.5	2067.3	1995.9	2412.6	2558.4	2162.7	2083.2	1850.4	2356.3
Other Income	23.5	31	34.2	45.4	49.7	54.6	60.5	51.8	22.7	21.3
Operating Profit	711.2	621.4	942.4	1149.2	846.3	508	947.1	1068.3	697.1	503.8
Interest	1.4	0.2	1.6	2.3	2.1	1.7	1.8	1.9	1.5	2
Exceptional Items										-201.9
PBDT	709.8	621.2	940.8	1146.9	844.2	506.3	945.3	1066.4	695.6	299.9
Depreciation	61.2	74.7	74.8	97.5	58.9	65	64.8	69.2	68.4	71.6
Profit Before Tax	648.6	546.5	866	1049.4	785.3	441.3	880.5	997.2	627.2	228.3
Tax	137	134.6	229.4	281.4	193.4	143.1	224.8	276.5	161.6	60.5
Profit After Tax	511.6	411.9	636.6	768	591.9	298.2	655.7	720.7	465.6	167.8
Net Profit	511.6	411.9	636.6	768	591.9	298.2	655.7	720.7	465.6	167.8
Equity Capital	166	166	166	166	166	166	166	166	166	166
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	30.82	24.81	38.35	46.27	35.66	17.96	39.5	43.42	28.05	10.11
Diluted Eps After Extraordinary Items	30.8	24.8	38.3	46.3	35.7	17.96	39.5	43.4	28	10.11
Diluted Eps Before Extraordinary Items	30.8	24.8	38.3	46.3	35.7	17.96	39.5	43.4	28	10.11

STANDALONE QUARTERLY RESULT FOR PROCTER & GAMBLE HEALTH LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	2678.2	2958.9	2975.5	3099.7	3209.2	3011.8	3049.3	3099.7	2524.8	2838.8
Total Income	2701.7	2989.9	3009.7	3145.1	3258.9	3066.4	3109.8	3151.5	2547.5	2860.1
Total Expenditure	1990.5	2368.5	2067.3	1995.9	2412.6	2558.4	2162.7	2083.2	1850.4	2356.3
Other Income	23.5	31	34.2	45.4	49.7	54.6	60.5	51.8	22.7	21.3
Operating Profit	711.2	621.4	942.4	1149.2	846.3	508	947.1	1068.3	697.1	503.8
Interest	1.4	0.2	1.6	2.3	2.1	1.7	1.8	1.9	1.5	2
Exceptional Items										-201.9
PBDT	709.8	621.2	940.8	1146.9	844.2	506.3	945.3	1066.4	695.6	299.9
Depreciation	61.2	74.7	74.8	97.5	58.9	65	64.8	69.2	68.4	71.6
Profit Before Tax	648.6	546.5	866	1049.4	785.3	441.3	880.5	997.2	627.2	228.3
Tax	137	134.6	229.4	281.4	193.4	143.1	224.8	276.5	161.6	60.5
Profit After Tax	511.6	411.9	636.6	768	591.9	298.2	655.7	720.7	465.6	167.8
Net Profit	511.6	411.9	636.6	768	591.9	298.2	655.7	720.7	465.6	167.8
Equity Capital	166	166	166	166	166	166	166	166	166	166
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	30.82	24.81	38.35	46.27	35.66	17.96	39.5	43.42	28.05	10.11
Diluted Eps After Extraordinary Items	30.8	24.8	38.3	46.3	35.7	17.96	39.5	43.4	28	10.11
Diluted Eps Before Extraordinary Items	30.8	24.8	38.3	46.3	35.7	17.96	39.5	43.4	28	10.11

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR PROCTER & GAMBLE HEALTH LIMITED

Date End	Jun 2021	Jun 2022	Jun 2023	Jun 2024
No of months	12 months	12 months	12 months	12 months
Net Sales	10087.3	11144.1	12296.2	11512.6
Total Income	10268.3	11276	12480.1	11668.9
Total Expenditure	7627.1	8467.3	9049.4	8452.6
Other Income	181	131.9	183.9	156.3
Operating Profit	2641.2	2808.7	3430.7	3216.3
Interest	8	4.2	7.7	7.2
Exceptional Items				-201.9
PBDT	2633.2	2804.5	3423	3007.2
Depreciation	300.4	270.8	281	274
Profit Before Tax	2332.8	2533.7	3142	2733.2
Tax	564.8	608.5	847.3	723.4
Profit After Tax	1768	1925.2	2294.7	2009.8
Net Profit	1768	1925.2	2294.7	2009.8
Equity Capital	166	166	166	166
Face Value (IN RS)	10	10	10	10
Reserves	6871.1	5998.9		5216.4
Calculated EPS	106.51	115.98	138.24	121.07
Diluted Eps After Extraordinary Items	106.5	116	138.23	121.07
Diluted Eps Before Extraordinary Items	106.5	116	138.23	121.07

STANDALONE ANNUAL RESULT FOR PROCTER & GAMBLE HEALTH LIMITED

Date End	Jun 2021	Jun 2022	Jun 2023	Jun 2024
No of months	12 months	12 months	12 months	12 months
Net Sales	10087.3	11144.1	12296.2	11512.6
Total Income	10268.3	11276	12480.1	11668.9
Total Expenditure	7627.1	8467.3	9049.4	8452.6
Other Income	181	131.9	183.9	156.3
Operating Profit	2641.2	2808.7	3430.7	3216.3
Interest	8	4.2	7.7	7.2
Exceptional Items				-201.9
PBDT	2633.2	2804.5	3423	3007.2
Depreciation	300.4	270.8	281	274
Profit Before Tax	2332.8	2533.7	3142	2733.2
Tax	564.8	608.5	847.3	723.4
Profit After Tax	1768	1925.2	2294.7	2009.8
Net Profit	1768	1925.2	2294.7	2009.8
Equity Capital	166	166	166	166
Face Value (IN RS)	10	10	10	10
Reserves	6871.1	5998.9		5216.4
Calculated EPS	106.51	115.98	138.24	121.07
Diluted Eps After Extraordinary Items	106.5	116	138.23	121.07
Diluted Eps Before Extraordinary Items	106.5	116	138.23	121.07

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR PROCTER & GAMBLE HEALTH LIMITED

YEAR	Jun 2020	Jun 2021	Jun 2022	Jun 2023
No of Months	18 months	12 months	12 months	12 months
Gross Sales	1355.86 Cr	1008.73 Cr	1114.41 Cr	1328.24 Cr
Sales	1329.21 Cr	990.79 Cr	1092.04 Cr	1304.48 Cr
Processing Charges / Service Income	25.27 Cr	16.93 Cr	19.45 Cr	22.38 Cr
Net Sales	1355.86 Cr	1008.73 Cr	1114.41 Cr	1229.62 Cr
Increase/Decrease in Stock	-13.03 Cr	4.54 Cr	-4.75 Cr	2.85 Cr
Raw Material Consumed	444.47 Cr	310.28 Cr	344.55 Cr	358.99 Cr
Opening Raw Materials	50.59 Cr	56.93 Cr	44.51 Cr	35.8 Cr
Purchases Raw Materials	422.44 Cr	276.64 Cr	315.01 Cr	338.69 Cr
Closing Raw Materials	56.93 Cr	44.45 Cr	35.8 Cr	55.26 Cr
Other Direct Purchases / Brought in cost	28.37 Cr	21.16 Cr	20.83 Cr	39.76 Cr
Power & Fuel Cost	19.09 Cr	12.97 Cr	14.7 Cr	12.88 Cr
Electricity & Power	19.09 Cr	12.97 Cr	14.7 Cr	12.88 Cr
Employee Cost	182.93 Cr	150.47 Cr	167.56 Cr	206.17 Cr
Salaries, Wages & Bonus	153.23 Cr	125.59 Cr	132.07 Cr	173.44 Cr
Contributions to EPF & Pension Funds	8.75 Cr	7.74 Cr	14.36 Cr	14.99 Cr
Workmen and Staff Welfare Expenses	15.15 Cr	9.33 Cr	13.02 Cr	17.32 Cr
Other Manufacturing Expenses	122.71 Cr	85.33 Cr	132.01 Cr	126.07 Cr
Sub-contracted / Out sourced services	0	0	12.66 Cr	13.5 Cr
Processing Charges	69.3 Cr	45.65 Cr	43.76 Cr	42.17 Cr
Repairs and Maintenance	12.28 Cr	11.3 Cr	8.07 Cr	8.87 Cr
General and Administration Expenses	153.23 Cr	96.34 Cr	60.88 Cr	87.16 Cr
Rent , Rates & Taxes	25.27 Cr	5.33 Cr	7.5 Cr	22.62 Cr
Insurance	79 Lk	85 Lk	73 Lk	51 Lk
Printing and stationery	0	0	7.29 Cr	8.09 Cr
Professional and legal fees	39.05 Cr	46.22 Cr	21.6 Cr	22.85 Cr
Traveling and conveyance	39.53 Cr	10.87 Cr	22.34 Cr	31.2 Cr
Selling and Distribution Expenses	117.27 Cr	86.43 Cr	109.45 Cr	74.49 Cr
Advertisement & Sales Promotion	117.27 Cr	86.43 Cr	109.45 Cr	74.49 Cr
Miscellaneous Expenses	14.85 Cr	16.35 Cr	22.33 Cr	36.33 Cr
Bad debts /advances written off	1.3 Cr	0	7 Lk	0
Provision for doubtful debts	0	1.08 Cr	1.59 Cr	2.15 Cr
Loss on disposal of fixed assets(net)	3.25 Cr	42 Lk	54 Lk	0
Loss on foreign exchange fluctuations	0	0	69 Lk	0
Total Expenditure	1041.52 Cr	762.71 Cr	846.73 Cr	904.94 Cr
Other Income	69.96 Cr	18.1 Cr	13.19 Cr	18.39 Cr
Interest Received	57.25 Cr	15.06 Cr	11.07 Cr	14.33 Cr
Profit on sale of Fixed Assets	0	0	0	71 Lk
Provision Written Back	3.49 Cr	0	0	0
Foreign Exchange Gains	2.67 Cr	0	0	34 Lk
Operating Profit	384.3 Cr	264.12 Cr	280.87 Cr	343.07 Cr
Interest	0	80 Lk	42 Lk	77 Lk
PBDT	384.3 Cr	263.32 Cr	280.45 Cr	342.3 Cr
Depreciation	29.45 Cr	30.04 Cr	27.08 Cr	28.1 Cr
Profit Before Taxation & Exceptional Items	354.85 Cr	233.28 Cr	253.37 Cr	314.2 Cr
Profit Before Tax	354.85 Cr	233.28 Cr	253.37 Cr	314.2 Cr
Provision for Tax	100.77 Cr	56.48 Cr	60.85 Cr	84.73 Cr
Current Income Tax	102.78 Cr	63.6 Cr	65.02 Cr	86.61 Cr
Deferred Tax	5.99 Cr	-4.9 Cr	4 Lk	-5.06 Cr
Profit After Tax	254.08 Cr	176.8 Cr	192.52 Cr	229.47 Cr
Consolidated Net Profit	254.08 Cr	176.8 Cr	192.52 Cr	229.47 Cr
Profit Balance B/F	1167.97 Cr	532.26 Cr	327.7 Cr	237.07 Cr
Appropriations	1422.05 Cr	709.06 Cr	520.22 Cr	466.54 Cr
Other Appropriation	889.79 Cr	381.36 Cr	215.09 Cr	76.54 Cr
Equity Dividend %	2300	1300	525	950
Earnings Per Share	153.06	106.51	115.98	138.24
Adjusted EPS	153.06	106.51	115.98	138.24

STANDALONE PROFIT / LOSS FOR PROCTER & GAMBLE HEALTH LIMITED

YEAR	Jun 2020	Jun 2021	Jun 2022	Jun 2023
No of Months	18 months	12 months	12 months	12 months
Gross Sales	1355.86 Cr	1008.73 Cr	1114.41 Cr	1328.24 Cr
Sales	1329.21 Cr	990.79 Cr	1092.04 Cr	1304.48 Cr
Processing Charges / Service Income	25.27 Cr	16.93 Cr	19.45 Cr	22.38 Cr
Net Sales	1355.86 Cr	1008.73 Cr	1114.41 Cr	1229.62 Cr
Increase/Decrease in Stock	-13.03 Cr	4.54 Cr	-4.75 Cr	2.85 Cr
Raw Material Consumed	444.47 Cr	310.28 Cr	344.55 Cr	358.99 Cr
Opening Raw Materials	50.59 Cr	56.93 Cr	44.51 Cr	35.8 Cr
Purchases Raw Materials	422.44 Cr	276.64 Cr	315.01 Cr	338.69 Cr
Closing Raw Materials	56.93 Cr	44.45 Cr	35.8 Cr	55.26 Cr
Other Direct Purchases / Brought in cost	28.37 Cr	21.16 Cr	20.83 Cr	39.76 Cr
Power & Fuel Cost	19.09 Cr	12.97 Cr	14.7 Cr	12.88 Cr
Electricity & Power	19.09 Cr	12.97 Cr	14.7 Cr	12.88 Cr
Employee Cost	182.93 Cr	150.47 Cr	167.56 Cr	206.17 Cr
Salaries, Wages & Bonus	153.23 Cr	125.59 Cr	132.07 Cr	173.44 Cr
Contributions to EPF & Pension Funds	8.75 Cr	7.74 Cr	14.36 Cr	14.99 Cr
Workmen and Staff Welfare Expenses	15.15 Cr	9.33 Cr	13.02 Cr	17.32 Cr
Other Manufacturing Expenses	122.71 Cr	85.33 Cr	132.01 Cr	126.07 Cr
Sub-contracted / Out sourced services	0	0	12.66 Cr	13.5 Cr
Processing Charges	69.3 Cr	45.65 Cr	43.76 Cr	42.17 Cr
Repairs and Maintenance	12.28 Cr	11.3 Cr	8.07 Cr	8.87 Cr
General and Administration Expenses	153.23 Cr	96.34 Cr	60.88 Cr	87.16 Cr
Rent , Rates & Taxes	25.27 Cr	5.33 Cr	7.5 Cr	22.62 Cr
Insurance	79 Lk	85 Lk	73 Lk	51 Lk
Printing and stationery	0	0	7.29 Cr	8.09 Cr
Professional and legal fees	39.05 Cr	46.22 Cr	21.6 Cr	22.85 Cr
Traveling and conveyance	39.53 Cr	10.87 Cr	22.34 Cr	31.2 Cr
Selling and Distribution Expenses	117.27 Cr	86.43 Cr	109.45 Cr	74.49 Cr
Advertisement & Sales Promotion	117.27 Cr	86.43 Cr	109.45 Cr	74.49 Cr
Miscellaneous Expenses	14.85 Cr	16.35 Cr	22.33 Cr	36.33 Cr
Bad debts /advances written off	1.3 Cr	0	7 Lk	0
Provision for doubtful debts	0	1.08 Cr	1.59 Cr	2.15 Cr
Loss on disposal of fixed assets(net)	3.25 Cr	42 Lk	54 Lk	0
Loss on foreign exchange fluctuations	0	0	69 Lk	0
Total Expenditure	1041.52 Cr	762.71 Cr	846.73 Cr	904.94 Cr
Other Income	69.96 Cr	18.1 Cr	13.19 Cr	18.39 Cr
Interest Received	57.25 Cr	15.06 Cr	11.07 Cr	14.33 Cr
Profit on sale of Fixed Assets	0	0	0	71 Lk
Provision Written Back	3.49 Cr	0	0	0
Foreign Exchange Gains	2.67 Cr	0	0	34 Lk
Operating Profit	384.3 Cr	264.12 Cr	280.87 Cr	343.07 Cr
Interest	0	80 Lk	42 Lk	77 Lk
PBDT	384.3 Cr	263.32 Cr	280.45 Cr	342.3 Cr
Depreciation	29.45 Cr	30.04 Cr	27.08 Cr	28.1 Cr
Profit Before Taxation & Exceptional Items	354.85 Cr	233.28 Cr	253.37 Cr	314.2 Cr
Profit Before Tax	354.85 Cr	233.28 Cr	253.37 Cr	314.2 Cr
Provision for Tax	100.77 Cr	56.48 Cr	60.85 Cr	84.73 Cr
Current Income Tax	102.78 Cr	63.6 Cr	65.02 Cr	86.61 Cr
Deferred Tax	5.99 Cr	-4.9 Cr	4 Lk	-5.06 Cr
Profit After Tax	254.08 Cr	176.8 Cr	192.52 Cr	229.47 Cr
Consolidated Net Profit	254.08 Cr	176.8 Cr	192.52 Cr	229.47 Cr
Profit Balance B/F	1167.97 Cr	532.26 Cr	327.7 Cr	237.07 Cr
Appropriations	1422.05 Cr	709.06 Cr	520.22 Cr	466.54 Cr
Other Appropriation	889.79 Cr	381.36 Cr	215.09 Cr	76.54 Cr
Equity Dividend %	2300	1300	525	950
Earnings Per Share	153.06	106.51	115.98	138.24
Adjusted EPS	153.06	106.51	115.98	138.24

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR PROCTER & GAMBLE HEALTH LIMITED

Year End	Jun 2020	Jun 2021	Jun 2022	Jun 2023
No of Months	18 months	12 months	12 months	12 months
Profit Before Tax	354.85 Cr	233.28 Cr	253.37 Cr	314.2 Cr
Adjustment	-12.16 Cr	29.56 Cr	27.31 Cr	41.49 Cr
Changes In working Capital	-5.73 Cr	52.55 Cr	-47.3 Cr	-30.03 Cr
Cash Flow after changes in Working Capital	336.96 Cr	315.39 Cr	233.38 Cr	325.66 Cr
Cash Flow from Operating Activities	235.37 Cr	247.26 Cr	169.52 Cr	236 Cr
Cash Flow from Investing Activities	164.64 Cr	-32.27 Cr	-25.54 Cr	-21.5 Cr
Cash Flow from Financing Activitie	-883.41 Cr	-386.63 Cr	-288.63 Cr	-98.47 Cr
Net Cash Inflow / Outflow	-483.4 Cr	-171.64 Cr	-144.65 Cr	116.03 Cr
Opening Cash & Cash Equivalents	1119.09 Cr	635.69 Cr	464.05 Cr	319.39 Cr
Closing Cash & Cash Equivalent	635.69 Cr	464.05 Cr	319.4 Cr	435.42 Cr

STANDALONE CASH FLOW FOR PROCTER & GAMBLE HEALTH LIMITED

Year End	Jun 2020	Jun 2021	Jun 2022	Jun 2023
No of Months	18 months	12 months	12 months	12 months
Profit Before Tax	354.85 Cr	233.28 Cr	253.37 Cr	314.2 Cr
Adjustment	-12.16 Cr	29.56 Cr	27.31 Cr	41.49 Cr
Changes In working Capital	-5.73 Cr	52.55 Cr	-47.3 Cr	-30.03 Cr
Cash Flow after changes in Working Capital	336.96 Cr	315.39 Cr	233.38 Cr	325.66 Cr
Cash Flow from Operating Activities	235.37 Cr	247.26 Cr	169.52 Cr	236 Cr
Cash Flow from Investing Activities	164.64 Cr	-32.27 Cr	-25.54 Cr	-21.5 Cr
Cash Flow from Financing Activitie	-883.41 Cr	-386.63 Cr	-288.63 Cr	-98.47 Cr
Net Cash Inflow / Outflow	-483.4 Cr	-171.64 Cr	-144.65 Cr	116.03 Cr
Opening Cash & Cash Equivalents	1119.09 Cr	635.69 Cr	464.05 Cr	319.39 Cr
Closing Cash & Cash Equivalent	635.69 Cr	464.05 Cr	319.4 Cr	435.42 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR PROCTER & GAMBLE HEALTH LIMITED

YEAR	Jun 2020	Jun 2021	Jun 2022	Jun 2023
Share Capital	16.6 Cr	16.6 Cr	16.6 Cr	16.6 Cr
Equity - Authorised	18 Cr	18 Cr	18 Cr	18 Cr
Equity - Issued	16.6 Cr	16.6 Cr	16.6 Cr	16.6 Cr
Equity Paid Up	16.6 Cr	16.6 Cr	16.6 Cr	16.6 Cr
Face Value	10	10	10	10
Total Reserves	887.8 Cr	683.24 Cr	592.61 Cr	726.45 Cr
Securities Premium	11.13 Cr	11.13 Cr	11.13 Cr	11.13 Cr
Capital Reserves	26 Lk	26 Lk	26 Lk	26 Lk
Profit & Loss Account Balance	532.26 Cr	327.7 Cr	237.07 Cr	370.91 Cr
General Reserves	343.89 Cr	343.89 Cr	343.89 Cr	343.89 Cr
Reserve excluding Revaluation Reserve	887.8 Cr	683.24 Cr	592.61 Cr	726.45 Cr
Shareholder's Funds	906.34 Cr	703.71 Cr	616.49 Cr	750.89 Cr
Deferred Tax Assets / Liabilities	-15.15 Cr	-19.91 Cr	-19.65 Cr	-25.32 Cr
Deferred Tax Assets	15.79 Cr	19.91 Cr	19.65 Cr	25.32 Cr
Deferred Tax Liability	64 Lk	0	0	0
Other Long Term Liabilities	1.21 Cr	3.43 Cr	60 Lk	9.53 Cr
Long Term Provisions	681.1 Cr	739.9 Cr	734.35 Cr	818.79 Cr
Total Non-Current Liabilities	667.16 Cr	723.42 Cr	715.3 Cr	803 Cr
Trade Payables	123.96 Cr	128.76 Cr	176.01 Cr	237.04 Cr
Sundry Creditors	123.96 Cr	128.76 Cr	176.01 Cr	237.04 Cr
Other Current Liabilities	94.51 Cr	104.1 Cr	42.32 Cr	42.48 Cr
Advances received from customers	1.22 Cr	1.2 Cr	56 Lk	55 Lk
Short Term Provisions	320.15 Cr	317.82 Cr	393.33 Cr	399.56 Cr
Provision for Tax	315.79 Cr	315.96 Cr	383.07 Cr	381.31 Cr
Total Current Liabilities	538.62 Cr	550.68 Cr	611.66 Cr	679.08 Cr
Total Liabilities	2112.12 Cr	1977.81 Cr	1943.45 Cr	2232.97 Cr
Gross Block	199.57 Cr	214.9 Cr	241.11 Cr	263.07 Cr
Less: Accumulated Depreciation	77.2 Cr	113.94 Cr	132.05 Cr	121.35 Cr
Less: Impairment of Assets	24.45 Cr	0	0	0
Net Block	97.92 Cr	100.96 Cr	109.06 Cr	141.72 Cr
Capital Work in Progress	21.45 Cr	39.15 Cr	40.6 Cr	32.49 Cr
Non Current Investments	3.3 Cr	2.95 Cr	0	0
Long Term Investment	3.3 Cr	2.95 Cr	0	0
Unquoted	3.3 Cr	2.95 Cr	0	0
Long Term Loans & Advances	721.98 Cr	795.9 Cr	801.72 Cr	885.23 Cr
Total Non-Current Assets	844.65 Cr	938.96 Cr	953.98 Cr	1061.69 Cr
Unquoted	3.3 Cr	2.95 Cr	0	0
Inventories	134.11 Cr	118.37 Cr	115.21 Cr	134.94 Cr
Raw Materials	56.93 Cr	44.45 Cr	35.8 Cr	55.26 Cr
Work-in Progress	16.05 Cr	10.39 Cr	10.92 Cr	13.56 Cr
Finished Goods	48.82 Cr	50.59 Cr	54.77 Cr	49.28 Cr
Packing Materials	11.36 Cr	12.11 Cr	12.67 Cr	13.9 Cr
Stores and Spare	30 Lk	83 Lk	1.05 Cr	2.94 Cr
Sundry Debtors	95.27 Cr	59.43 Cr	83.44 Cr	115.71 Cr
Debtors more than Six months	0	0	52 Lk	9.6 Cr
Debtors Others	95.97 Cr	61.21 Cr	85.63 Cr	110.06 Cr
Cash and Bank	639.09 Cr	468.91 Cr	324.53 Cr	440.22 Cr
Balances at Bank	639.09 Cr	464.34 Cr	324.53 Cr	440.22 Cr
Other Current Assets	7.76 Cr	6.75 Cr	7.95 Cr	13.73 Cr
Interest accrued on Investments	2.58 Cr	32 Lk	98 Lk	1.12 Cr
Prepaid Expenses	3.75 Cr	77 Lk	49 Lk	1.17 Cr
Short Term Loans and Advances	391.24 Cr	385.39 Cr	458.34 Cr	466.68 Cr
Advances recoverable in cash or in kind	2.46 Cr	1.7 Cr	2.52 Cr	6.06 Cr
Advance income tax and TDS	311.28 Cr	311.71 Cr	375.83 Cr	375.18 Cr
Total Current Assets	1267.47 Cr	1038.85 Cr	989.47 Cr	1171.28 Cr
Net Current Assets (Including Current Investments)	728.85 Cr	488.17 Cr	377.81 Cr	492.2 Cr
Total Assets	2112.12 Cr	1977.81 Cr	1943.45 Cr	2232.97 Cr
Contingent Liabilities	158.78 Cr	184.37 Cr	181.19 Cr	156.51 Cr
Book Value	544.82	421.59	366.99	447.62
Adjusted Book Value	544.82	421.59	366.99	447.62

STANDALONE BALANCE SHEET FOR PROCTER & GAMBLE HEALTH LIMITED

YEAR	Jun 2020	Jun 2021	Jun 2022	Jun 2023
Share Capital	16.6 Cr	16.6 Cr	16.6 Cr	16.6 Cr
Equity - Authorised	18 Cr	18 Cr	18 Cr	18 Cr
Equity - Issued	16.6 Cr	16.6 Cr	16.6 Cr	16.6 Cr
Equity Paid Up	16.6 Cr	16.6 Cr	16.6 Cr	16.6 Cr
Face Value	10	10	10	10
Total Reserves	887.8 Cr	683.24 Cr	592.61 Cr	726.45 Cr
Securities Premium	11.13 Cr	11.13 Cr	11.13 Cr	11.13 Cr
Capital Reserves	26 Lk	26 Lk	26 Lk	26 Lk
Profit & Loss Account Balance	532.26 Cr	327.7 Cr	237.07 Cr	370.91 Cr
General Reserves	343.89 Cr	343.89 Cr	343.89 Cr	343.89 Cr
Reserve excluding Revaluation Reserve	887.8 Cr	683.24 Cr	592.61 Cr	726.45 Cr
Shareholder's Funds	906.34 Cr	703.71 Cr	616.49 Cr	750.89 Cr
Deferred Tax Assets / Liabilities	-15.15 Cr	-19.91 Cr	-19.65 Cr	-25.32 Cr
Deferred Tax Assets	15.79 Cr	19.91 Cr	19.65 Cr	25.32 Cr
Deferred Tax Liability	64 Lk	0	0	0
Other Long Term Liabilities	1.21 Cr	3.43 Cr	60 Lk	9.53 Cr
Long Term Provisions	681.1 Cr	739.9 Cr	734.35 Cr	818.79 Cr
Total Non-Current Liabilities	667.16 Cr	723.42 Cr	715.3 Cr	803 Cr
Trade Payables	123.96 Cr	128.76 Cr	176.01 Cr	237.04 Cr
Sundry Creditors	123.96 Cr	128.76 Cr	176.01 Cr	237.04 Cr
Other Current Liabilities	94.51 Cr	104.1 Cr	42.32 Cr	42.48 Cr
Advances received from customers	1.22 Cr	1.2 Cr	56 Lk	55 Lk
Short Term Provisions	320.15 Cr	317.82 Cr	393.33 Cr	399.56 Cr
Provision for Tax	315.79 Cr	315.96 Cr	383.07 Cr	381.31 Cr
Total Current Liabilities	538.62 Cr	550.68 Cr	611.66 Cr	679.08 Cr
Total Liabilities	2112.12 Cr	1977.81 Cr	1943.45 Cr	2232.97 Cr
Gross Block	199.57 Cr	214.9 Cr	241.11 Cr	263.07 Cr
Less: Accumulated Depreciation	77.2 Cr	113.94 Cr	132.05 Cr	121.35 Cr
Less: Impairment of Assets	24.45 Cr	0	0	0
Net Block	97.92 Cr	100.96 Cr	109.06 Cr	141.72 Cr
Capital Work in Progress	21.45 Cr	39.15 Cr	40.6 Cr	32.49 Cr
Non Current Investments	3.3 Cr	2.95 Cr	0	0
Long Term Investment	3.3 Cr	2.95 Cr	0	0
Unquoted	3.3 Cr	2.95 Cr	0	0
Long Term Loans & Advances	721.98 Cr	795.9 Cr	801.72 Cr	885.23 Cr
Total Non-Current Assets	844.65 Cr	938.96 Cr	953.98 Cr	1061.69 Cr
Unquoted	3.3 Cr	2.95 Cr	0	0
Inventories	134.11 Cr	118.37 Cr	115.21 Cr	134.94 Cr
Raw Materials	56.93 Cr	44.45 Cr	35.8 Cr	55.26 Cr
Work-in Progress	16.05 Cr	10.39 Cr	10.92 Cr	13.56 Cr
Finished Goods	48.82 Cr	50.59 Cr	54.77 Cr	49.28 Cr
Packing Materials	11.36 Cr	12.11 Cr	12.67 Cr	13.9 Cr
Stores and Spare	30 Lk	83 Lk	1.05 Cr	2.94 Cr
Sundry Debtors	95.27 Cr	59.43 Cr	83.44 Cr	115.71 Cr
Debtors more than Six months	0	0	52 Lk	9.6 Cr
Debtors Others	95.97 Cr	61.21 Cr	85.63 Cr	110.06 Cr
Cash and Bank	639.09 Cr	468.91 Cr	324.53 Cr	440.22 Cr
Balances at Bank	639.09 Cr	464.34 Cr	324.53 Cr	440.22 Cr
Other Current Assets	7.76 Cr	6.75 Cr	7.95 Cr	13.73 Cr
Interest accrued on Investments	2.58 Cr	32 Lk	98 Lk	1.12 Cr
Prepaid Expenses	3.75 Cr	77 Lk	49 Lk	1.17 Cr
Short Term Loans and Advances	391.24 Cr	385.39 Cr	458.34 Cr	466.68 Cr
Advances recoverable in cash or in kind	2.46 Cr	1.7 Cr	2.52 Cr	6.06 Cr
Advance income tax and TDS	311.28 Cr	311.71 Cr	375.83 Cr	375.18 Cr
Total Current Assets	1267.47 Cr	1038.85 Cr	989.47 Cr	1171.28 Cr
Net Current Assets (Including Current Investments)	728.85 Cr	488.17 Cr	377.81 Cr	492.2 Cr
Total Assets	2112.12 Cr	1977.81 Cr	1943.45 Cr	2232.97 Cr
Contingent Liabilities	158.78 Cr	184.37 Cr	181.19 Cr	156.51 Cr
Book Value	544.82	421.59	366.99	447.62
Adjusted Book Value	544.82	421.59	366.99	447.62

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR PROCTER & GAMBLE HEALTH LIMITED

YEAR	Jun 2020	Jun 2021	Jun 2022	Jun 2023
Operational & Financial Ratios
Earnings Per Share (Rs)	153.06	106.51	115.98	138.24
CEPS(Rs)	170.8	124.6	132.29	155.16
DPS(Rs)	230	130	52.5	95
Book NAV/Share(Rs)	544.82	421.59	366.99	447.62
Tax Rate(%)	28.4	24.21	24.02	26.97
Margin Ratios
Core EBITDA Margin(%)	23.18	24.39	24.02	24.44
EBIT Margin(%)	26.17	23.21	22.77	23.71
Pre Tax Margin(%)	26.17	23.13	22.74	23.66
PAT Margin (%)	18.74	17.53	17.28	17.28
Cash Profit Margin (%)	20.91	20.51	19.71	19.39
Performance Ratios
ROA(%)	10.82	8.65	9.82	11
ROE(%)	20.79	22.04	29.41	33.94
ROCE(%)	29.01	29.08	38.45	46.07
Asset Turnover(x)	0.58	0.49	0.57	0.64
Sales/Fixed Asset(x)	7.04	4.87	4.89	5.27
Working Capital/Sales(x)	1.86	2.07	2.95	2.7
Efficiency Ratios
Fixed Capital/Sales(x)	0.14	0.21	0.2	0.19
Receivable days	21.73	27.99	23.46	27.36
Inventory Days	33.31	45.68	38.25	34.37
Payable days	43.33	67.62	190.62	206.35
Valuation Parameters
PER(x)	26.57	52.52	36.1	37.97
PCE(x)	23.81	44.89	31.65	33.83
Price/Book(x)	7.47	13.27	11.41	11.73
Yield(%)	5.66	2.32	1.25	1.81
EV/Net Sales(x)	4.51	8.74	5.95	6.73
EV/Core EBITDA(x)	15.91	33.38	23.59	24.12
EV/EBIT(x)	17.23	37.67	26.11	26.27
EV/CE(x)	2.89	4.46	3.41	3.71
M Cap / Sales	4.98	9.21	6.24	7.09
Growth Ratio
Net Sales Growth(%)	5.26	-25.6	10.48	10.34
Core EBITDA Growth(%)	-58.79	-31.27	6.34	22.15
EBIT Growth(%)	-61.34	-34.03	8.42	24.11
PAT Growth(%)	-69.71	-30.42	8.89	19.19
EPS Growth(%)	-69.71	-30.42	8.89	19.19
Financial Stability Ratios
Current Ratio(x)	2.35	1.89	1.62	1.72
Quick Ratio(x)	2.1	1.67	1.43	1.53
Interest Cover(x)	0	292.6	604.26	409.05

FINANCIAL RATIOS (STANDALONE) FOR PROCTER & GAMBLE HEALTH LIMITED

YEAR	Jun 2020	Jun 2021	Jun 2022	Jun 2023
Operational & Financial Ratios
Earnings Per Share (Rs)	153.06	106.51	115.98	138.24
CEPS(Rs)	170.8	124.6	132.29	155.16
DPS(Rs)	230	130	52.5	95
Book NAV/Share(Rs)	544.82	421.59	366.99	447.62
Tax Rate(%)	28.4	24.21	24.02	26.97
Margin Ratios
Core EBITDA Margin(%)	23.18	24.39	24.02	24.44
EBIT Margin(%)	26.17	23.21	22.77	23.71
Pre Tax Margin(%)	26.17	23.13	22.74	23.66
PAT Margin (%)	18.74	17.53	17.28	17.28
Cash Profit Margin (%)	20.91	20.51	19.71	19.39
Performance Ratios
ROA(%)	10.82	8.65	9.82	11
ROE(%)	20.79	22.04	29.41	33.94
ROCE(%)	29.01	29.08	38.45	46.07
Asset Turnover(x)	0.58	0.49	0.57	0.64
Sales/Fixed Asset(x)	7.04	4.87	4.89	5.27
Working Capital/Sales(x)	1.86	2.07	2.95	2.7
Efficiency Ratios
Fixed Capital/Sales(x)	0.14	0.21	0.2	0.19
Receivable days	21.73	27.99	23.46	27.36
Inventory Days	33.31	45.68	38.25	34.37
Payable days	43.33	67.62	190.62	206.35
Valuation Parameters
PER(x)	26.57	52.52	36.1	37.97
PCE(x)	23.81	44.89	31.65	33.83
Price/Book(x)	7.47	13.27	11.41	11.73
Yield(%)	5.66	2.32	1.25	1.81
EV/Net Sales(x)	4.51	8.74	5.95	6.73
EV/Core EBITDA(x)	15.91	33.38	23.59	24.12
EV/EBIT(x)	17.23	37.67	26.11	26.27
EV/CE(x)	2.89	4.46	3.41	3.71
M Cap / Sales	4.98	9.21	6.24	7.09
Growth Ratio
Net Sales Growth(%)	5.26	-25.6	10.48	10.34
Core EBITDA Growth(%)	-58.79	-31.27	6.34	22.15
EBIT Growth(%)	-61.34	-34.03	8.42	24.11
PAT Growth(%)	-69.71	-30.42	8.89	19.19
EPS Growth(%)	-69.71	-30.42	8.89	19.19
Financial Stability Ratios
Current Ratio(x)	2.35	1.89	1.62	1.72
Quick Ratio(x)	2.1	1.67	1.43	1.53
Interest Cover(x)	0	292.6	604.26	409.05

SHARE HOLDING PATTERN FOR PROCTER & GAMBLE HEALTH LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
FII %	6.47	6.05	6.33	6.72	7.15	7.38	7.60	6.24	6.39	6.61
DII %	0.00	0.06	0.05	0.10	0.11	0.18	0.27	0.31	0.31	0.30
Public %	33.64	29.47	29.42	29.15	28.74	28.50	27.92	28.21	27.23	26.74

PEER COMPARISON FOR PROCTER & GAMBLE HEALTH LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR PROCTER &

Exchange Date	Purpose	Book Closure Dates
BSE 27-Sep-2024	Board Meeting - Quarterly Results	04-Nov-2024
BSE 22-Aug-2024	Dividend - Rs.60.0000 per share(600%)Final Dividend
BSE 22-Aug-2024	Book Closure - Rs.60.0000 per share(600%)Final Dividend & A.G.M.	29-Nov-2024 05-Dec-2024
BSE 22-Aug-2024	AGM - Rs.60.0000 per share(600%)Final Dividend & A.G.M.	05-Dec-2024 05-Dec-2024
BSE 28-Jun-2024	Board Meeting - Audited Results & Final Dividend	21-Aug-2024
BSE 27-Mar-2024	Board Meeting - Quarterly Results	02-May-2024
BSE 14-Feb-2024	Dividend - Interim Dividend
BSE 12-Jan-2024	Board Meeting - Quarterly Results & Interim Dividend	06-Feb-2024
BSE 23-Nov-2023	Dividend - Rs.50.0000 per share(500%)Final Dividend & A.G.M.	24-Nov-2023 30-Nov-2023
BSE 23-Oct-2023	Book Closure - Rs.50.0000 per share(500%)Final Dividend & A.G.M.	24-Nov-2023 30-Nov-2023
BSE 27-Sep-2023	Board Meeting - Quarterly Results	03-Nov-2023
BSE 24-Aug-2023	Book Closure - 18/12/2023 Equity Rs.50.0000 per share(500%)Final Dividend & A.G.M.	15-Nov-2023 21-Nov-2023
BSE 24-Aug-2023	AGM - 18/12/2023 Equity Rs.50.0000 per share(500%)Final Dividend & A.G.M.	21-Nov-2023 21-Nov-2023
BSE 24-Aug-2023	Dividend - Rs.50.0000 per share(500%)Final Dividend
BSE 17-Jul-2023	Board Meeting - Final Dividend & Audited Results	23-Aug-2023
BSE 24-Apr-2023	Board Meeting - Quarterly Results	15-May-2023
BSE 13-Feb-2023	Dividend - Interim Dividend
BSE 18-Jan-2023	Dividend - Interim Dividend
BSE 16-Jan-2023	Board Meeting - Quarterly Results (Revised) & Interim Dividend	05-Feb-2023
BSE 09-Jan-2023	Board Meeting - Quarterly Results & Interim Dividend	08-Feb-2023
BSE 24-Nov-2022	AGM - We would like to inform you that the 55th Annual General Meeting of the Company was held on November 23, 2022 at 3.30 p.m. through Video Conference / Other Audio-Visual Means. In this respect, please find enclosed below:1. Voting results in respect of the business conducted at the Annual General Meeting, as required under Regulation 44 (3) of the SEBI (Listing Obligations & Disclosure Requirements...	23-Nov-2022
BSE 17-Oct-2022	Board Meeting - Quarterly Results (Revised)	11-Nov-2022
BSE 07-Oct-2022	Board Meeting - Quarterly Results	09-Nov-2022
BSE 09-Sep-2022	Book Closure - Rs.11.5000 per share(115%)Final Dividend & A.G.M.	17-Nov-2022 23-Nov-2022
BSE 09-Sep-2022	AGM - Rs.11.5000 per share(115%)Final Dividend & A.G.M.	23-Nov-2022 23-Nov-2022
BSE 29-Aug-2022	Dividend - Rs.11.5000 per share(115%)Final Dividend
BSE 05-Aug-2022	Board Meeting - Final Dividend & Audited Results	29-Aug-2022
BSE 12-May-2022	Dividend - Interim Dividend
BSE 30-Mar-2022	Board Meeting - Quarterly Results	05-May-2022
BSE 17-Jan-2022	Board Meeting - Quarterly Results	09-Feb-2022

CORPORATE ANNOUNCEMENTS FOR PROCTER &

Exchange Date	Category File	Description
BSE 19-Jan-2023	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 With reference to above captioned subject on the basis of confirmation received from our Registrar and Transfer Agent Kfin Technologies Limited ( formerly known as Kfin Technologies Private Limited) we confirm that the details of securities dematerialised during the quarter ended December 31 2022 as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 have been furnished to the stock exchanges where the shares of the Company are listed within the prescribed time period.We enclose herewith the copy of letter received from Kfin Technologies Limited confirming the above.
BSE 16-Jan-2023	Intimation FILE	Corporate Action-Board to consider Dividend With reference to the announcement dated January 09 2023 and in terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is now rescheduled to be held on Sunday February 5 2023 inter alia to consider and approve the unaudited financial results for the quarter ended December 31 2022.We would like to further inform you that the Board at the said meeting would also consider the declaration of interim dividend for the Financial Year 2022-23. The record date for payment of the Interim dividend if declared at the Board meeting will be Monday February 13 2023.
BSE 16-Jan-2023	Intimation FILE	Board Meeting Intimation for Intimation Of The Board Meeting Scheduled To Be Held On February 05 2023 Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2023 inter alia to consider and approve With reference to the announcement dated January 09 2023 and in terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is now rescheduled to be held on Sunday February 5 2023 inter alia to consider and approve the unaudited financial results for the quarter ended December 31 2022.We would like to further inform you that the Board at the said meeting would also consider the declaration of interim dividend for the Financial Year 2022-23. The record date for payment of the Interim dividend if declared at the Board meeting will be Monday February 13 2023.
BSE 09-Jan-2023	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate We have been informed by our Registrars and Share Transfer Agents (RTA) KFin Technologies Limited on January 07 2023 regarding the loss /misplacement of the share certificate(s)
BSE 09-Jan-2023	Intimation FILE	Board Meeting Intimation for Unaudited Financial Results And The Declaration Of Interim Dividend If Any. Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday February 8 2023 inter alia to consider and approve the unaudited financial results for the quarter ended December 31 2022 and the declaration of interim dividend for the Financial Year 2022-23 if any.Kindly take the same on record.
BSE 28-Jun-2022	Intimation FILE	Closure of Trading Window We would like to inform you that the Trading Window of the Company shall remain closed for Directors and designated employees from July 1 2022 until 48 hours from the publication of the audited financial results for quarter and Financial Year ended June 30 2022.Kindly take the same on record.
BSE 21-Jun-2022	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company on June 17 2022.We request you to take the same on record and acknowledge the receipt.
BSE 17-Jun-2022	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 we hereby inform you regarding issue of duplicate share certificate(s) to theshareholder(s) of the Company on June 17 2022 .We request you to take the same on record and acknowledge the receipt.
BSE 06-Jun-2022	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate We have been informed by our Registrars and Share Transfer Agents (RTA) KFin Technologies Limited on June 03 2022 regarding the loss /misplacement of share certificate(s).We request you to take the same on record and acknowledge receipt
BSE 06-May-2022	General Announcements FILE	Communication In Respect Of Deduction Of Tax At Source (TDS) On The Amount Of Dividend Income From Procter & Gamble Health Limited ('The Company') In accordance with the provisions of the Income Tax Act 1961 as amended by and read with the provisions of the Indian Finance Act 2020 dividend declared and paid by the Company after April 1 2020 is taxable in the hands of shareholders and the Company is required to deduct the tax at source (TDS).Shareholders holding shares in dematerialized mode are requested to update their records such as tax residential status permanent account number (PAN) and register their email addresses mobile numbers and other details with their relevant depositories through their depository participants. shareholders holding shares in physical mode are requested to furnish details to the Companys registrar and share transfer agent KFin Technologies Limited to determine the appropriate TDS rate (if any).
BSE 05-May-2022	Outcome FILE	Corporate Action-Board approves Dividend We are pleased to inform you that the Board of Directors of the Company at its meeting held today inter alia have recommended an Interim Dividend for the Financial Year 2021-22 of Rs. 41 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before May 31 2022. As informed earlier in our letter dated April 28 2022 record date for the purpose of eligibility for payment of said Interim Dividend shall be May 13 2022.
BSE 05-May-2022	Outcome FILE	Unaudited Financial Results For The Quarter Ended March 31 2022 And Interim Dividend For The Financial Year 2021-22 We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 6:00 p.m. and ended at 7: 20 p.m.) the Unaudited Financial Results for the quarter ended March 31 2022 were approved.We are enclosing herewith the following:a. Unaudited Financial Results for the quarter ended March 31 2022;b. Press Release; andc. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31 2022 furnished by Statutory Auditors of the Company.
BSE 05-May-2022	Outcome FILE	Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended March 31 2022 And Interim Dividend For The Financial Year 2021-22 We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 6:00 p.m. and ended at 7: 20 p.m.) the Unaudited Financial Results for the quarter ended March 31 2022 were approved.We are enclosing herewith the following:a. Unaudited Financial Results for the quarter ended March 31 2022;b. Press Release; andc. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31 2022 furnished by Statutory Auditors of the CompanyFurther we are pleased to inform you that the Board of Directors of the Company at its meeting held today inter alia have recommended an Interim Dividend for the Financial Year 2021-22 of Rs. 41 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before May 31 2022.
BSE 28-Apr-2022	Intimation FILE	Record Date For Payment Of The Interim Dividend If Declared At The Board Meeting We refer to our letter dated March 30 2022 informing that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 5 2022 to consider and approve Unaudited Financial Results for the quarter ended March 31 2022. We would like to further inform you that the Board at the said meeting would also consider declaration of interim dividend for the Financial Year 2021-22. The record date for payment of the Interim dividend if declared at the Board meeting will be Friday May 13 2022.Kindly take the same on record.
BSE 28-Apr-2022	Intimation FILE	Update on board meeting Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2022 inter alia to consider and approve We refer to our letter dated March 30 2022 informing that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 5 2022 to consider and approve Unaudited Financial Results for the quarter ended March 31 2022. We would like to further inform you that the Board at the said meeting would also consider declaration of interim dividend for the Financial Year 2021-22. The record date for payment of the Interim dividend if declared at the Board meeting will be Friday May 13 2022.Kindly take the same on record.
BSE 21-Apr-2022	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company on April 20 2022.We request you to take the same on record and acknowledge the receipt.
BSE 12-Apr-2022	General Announcements FILE	Change In Name Of Registrar And Share Transfer Agent We hereby bring to your notice that the Company has been intimated by its Registrar and Share Transfer Agent (RTA) of the change of its name from KFIN Technologies Private Limited to KFIN Technologies Limited pursuant to conversion into a Public Company with effect from 24th February 2022.Kindly take the same on record.
BSE 11-Apr-2022	Compliance -	Statement Of Investor Complaints For The Quarter Ended March 2022 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Zeal ShahDesignation :- Company Secretary and Compliance Officer
BSE 31-Mar-2022	Intimation FILE	Closure of Trading Window We would like to inform you that the Trading Window of the Company shall remain closed for Directors and designated employees from April 1 2022 until 48 hours from the publication of the unaudited financial results for the quarter ended March 31 2022.Kindly take the same on record.
BSE 30-Mar-2022	Intimation FILE	Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended March 31 2022 Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2022 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 05 2022 inter alia to consider and approve the unaudited financial results for the quarter ended March 31 2022Kindly take the same on record.
BSE 14-Mar-2022	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate We have been informed by our Registrars and Share Transfer Agents (RTA) KFin Technologies Private Limited regarding the loss /misplacement of the share certificate(s).We request you to take the same on record and acknowledge receipt.
BSE 18-Feb-2022	Regulation 23(9)- Disclosure of Related Party Transactions on consolidated basis FILE	Related Party Transactions For Six Months Ended December 31 2021 We are enclosing herewith the Related Party Transactions for six months ended December 31 2021.
BSE 09-Feb-2022	Outcome FILE	Unaudited Financial Results For The Quarter Ended December 31 2021 We are pleased to inform you that at the meeting of the Board of Directors of the Company held today the Unaudited Financial Results for the quarter ended December 31 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended December 31 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31 2021 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige
BSE 09-Feb-2022	Outcome FILE	Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended December 31 2021 We are pleased to inform you that at the meeting of the Board of Directors of the Company held today the Unaudited Financial Results for the quarter ended December 31 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended December 31 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31 2021 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige.
BSE 20-Jan-2022	General -	Shareholding for the Period Ended December 31 2021 Procter & Gamble Health Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31 2021. For more details kindly Click here
BSE 19-Jan-2022	Compliance -	Statement Of Investor Complaints For The Quarter Ended December 2021 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Zeal ShahDesignation :- Company Secretary and Compliance Officer
BSE 19-Jan-2022	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 With reference to above captioned subject on the basis of confirmation received from our Registrar and Transfer Agent Kfin Technologies Private Limited we confirm that the details of securities dematerialised during the quarter ended 31.12.2021 as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 have been furnished to the stock exchanges where the shares of the Company are listed within the prescribed time period.We enclose herewith the copy of letter received from Kfin Technologies Private Limited confirming the above.Kindly acknowledge receipt.
BSE 18-Jan-2022	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate We have been informed by our Registrars and Share Transfer Agents (RTA) KFin Technologies Private Limited regarding the loss /misplacement of the share certificate(s).We request you to take the same on record and acknowledge receipt.
BSE 17-Jan-2022	Intimation FILE	Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended December 31 2021 Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2022 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday February 9 2022 inter alia to consider and approve the unaudited financial results for the quarter ended December 31 2021.
BSE 31-Dec-2021	Outcome -	Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations 2015) Procter & Gamble Health Ltd has informed BSE regarding the details of Voting results of Postal Ballot under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
No Insider trading details found

BULK BLOCK DEALS FOR PROCTER & GAMBLE HEALTH LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 19-Sep-2022	Sell BLOCK	23,964 @ 4147.50	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	23,964 @ 4147.50	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 19-Sep-2022	Sell BLOCK	3,433 @ 4147.50	ISHARES INDIA SC MAURITIUS COMPANY
BSE 19-Sep-2022	Buy BLOCK	3,433 @ 4147.50	ISHARES MSCI INDIA SMALL-CAP ETF

DIVIDEND BY PROCTER & GAMBLE HEALTH LIMITED

Ex Dividend Date	Dividend Type	Dividend
21-Feb-2025	INTERIM DIVIDEND	80
28-Nov-2024	DIVIDEND	60
23-Nov-2023	DIVIDEND	50
13-Feb-2023	INTERIM DIVIDEND	45
15-Nov-2022	DIVIDEND	11.5
12-May-2022	INTERIM DIVIDEND	41
02-Nov-2021	DIVIDEND	40
02-Nov-2021	SPECIAL DIVIDEND	90
18-Nov-2020	DIVIDEND	42
18-Nov-2020	SPECIAL DIVIDEND	188